Entry |
|
Name |
Acetylsalicylic acid and lansoprazole; Acetylsalicylic acid and lansoprazole; Takelda (TN) |
Component |
|
Class |
Metabolizing enzyme substrate
DG01639 CYP2C19 substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
Remark |
Therapeutic category: | 3399 |
|
Efficacy |
Antithrombotic |
Comment |
Lansoprazole is primarily metabolized by CYP2C19 and CYP3A4.
|
Metabolism |
Enzyme: CYP2C19 [HSA: 1557], CYP3A4 [HSA: 1576]
|
Interaction |
|
Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B01 ANTITHROMBOTIC AGENTS
B01A ANTITHROMBOTIC AGENTS
B01AC Platelet aggregation inhibitors excl. heparin
B01AC56 Acetylsalicylic acid, combinations with proton pump inhibitors
D10527 Acetylsalicylic acid and lansoprazole <JP>
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
33 Blood and body fluid agents
339 Miscellaneous
3399 Others
D10527 Acetylsalicylic acid and lansoprazole
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01639 CYP2C19 substrate
D10527 Acetylsalicylic acid and lansoprazole
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D10527 Acetylsalicylic acid and lansoprazole
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10527
|
Other DBs |
|
LinkDB |
|